AbCellera Biologics Inc. Common Shares (ABCL) is a publicly traded Healthcare sector company. As of October 12, 2026, ABCL trades at $12.87 with a market cap of $4.07B and a P/E ratio of -23.32. ABCL moved +3.31% today. Year to date, ABCL is +266.81%; over the trailing twelve months it is +112.27%. Its 52-week range spans $1.89 to $15.02. Analyst consensus is strong buy with an average price target of $16.63. Rallies surfaces ABCL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AbCellera Biologics: UBS initiates coverage with buy rating and $18 target price: UBS initiated coverage of AbCellera Biologics with a buy rating and an $18 target price.
| Metric | Value |
|---|---|
| Price | $12.87 |
| Market Cap | $4.07B |
| P/E Ratio | -23.32 |
| EPS | $-0.54 |
| Dividend Yield | 0.00% |
| 52-Week High | $15.02 |
| 52-Week Low | $1.89 |
| Volume | 2.50M |
| Avg Volume | 0 |
| Revenue (TTM) | $66.17M |
| Net Income | $-164.66M |
| Gross Margin | 0.00% |
9 analysts cover ABCL: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.63.